Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib–Irinotecan Combo: A Case Study
Kailin Ding,1,* Xian Chen,2,* Yong Li,2 Wenzhu Li,2 Yongsong Ye,3 Tingting He,4 Wenjing Wang,4 Haibo Zhang2 1The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 2Department of Oncology, The Second Affiliated Hospital of Guangzhou Un...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-01-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/gastric-cancer-harboring-an-erbb3-mutation-treated-with-a-pyrotinibnda-peer-reviewed-article-OTT |
id |
doaj-166bda22df194a19983ae324dcfc940a |
---|---|
record_format |
Article |
spelling |
doaj-166bda22df194a19983ae324dcfc940a2021-01-19T20:55:25ZengDove Medical PressOncoTargets and Therapy1178-69302021-01-01Volume 1454555061290Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib–Irinotecan Combo: A Case StudyDing KChen XLi YLi WYe YHe TWang WZhang HKailin Ding,1,* Xian Chen,2,* Yong Li,2 Wenzhu Li,2 Yongsong Ye,3 Tingting He,4 Wenjing Wang,4 Haibo Zhang2 1The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 2Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 3Department of Imaging, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 4OrigiMed, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Haibo ZhangDepartment of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, People’s Republic of ChinaTel +86-20-81887233Email haibozh@gzucm.edu.cnAbstract: Gastric cancer is common, especially in East Asian countries, and is associated with high recurrence and mortality rates. Currently, there is no standard third-line treatment for metastatic gastric cancer. In this report, we present the case of a 69-year-old man with advanced gastric cancer, whose tumor was negative for human epidermal growth factor receptor 2 (HER2) according to immunohistochemical analysis. Next-generation sequencing performed on paraffin sections of the postoperative tumor samples indicated the presence of the ERBB3 V104L mutation. The patient received irinotecan plus pyrotinib as a third-line therapy and achieved a progression-free survival of 7.6 months with a high quality of life. Therefore, the combined administration of irinotecan and pyrotinib may improve the clinical condition of patients with gastric cancer harboring an ERBB3 mutation. Moreover, ERBB3 could be a potential therapeutic target for gastric cancer.Keywords: ERBB3, gastric cancer, irinotecan, pyrotinib, third-line therapyhttps://www.dovepress.com/gastric-cancer-harboring-an-erbb3-mutation-treated-with-a-pyrotinibnda-peer-reviewed-article-OTTerbb3gastric canceririnotecanpyrotinibthird-line therapy. |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ding K Chen X Li Y Li W Ye Y He T Wang W Zhang H |
spellingShingle |
Ding K Chen X Li Y Li W Ye Y He T Wang W Zhang H Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib–Irinotecan Combo: A Case Study OncoTargets and Therapy erbb3 gastric cancer irinotecan pyrotinib third-line therapy. |
author_facet |
Ding K Chen X Li Y Li W Ye Y He T Wang W Zhang H |
author_sort |
Ding K |
title |
Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib–Irinotecan Combo: A Case Study |
title_short |
Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib–Irinotecan Combo: A Case Study |
title_full |
Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib–Irinotecan Combo: A Case Study |
title_fullStr |
Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib–Irinotecan Combo: A Case Study |
title_full_unstemmed |
Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib–Irinotecan Combo: A Case Study |
title_sort |
gastric cancer harboring an erbb3 mutation treated with a pyrotinib–irinotecan combo: a case study |
publisher |
Dove Medical Press |
series |
OncoTargets and Therapy |
issn |
1178-6930 |
publishDate |
2021-01-01 |
description |
Kailin Ding,1,* Xian Chen,2,* Yong Li,2 Wenzhu Li,2 Yongsong Ye,3 Tingting He,4 Wenjing Wang,4 Haibo Zhang2 1The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 2Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 3Department of Imaging, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China; 4OrigiMed, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Haibo ZhangDepartment of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, People’s Republic of ChinaTel +86-20-81887233Email haibozh@gzucm.edu.cnAbstract: Gastric cancer is common, especially in East Asian countries, and is associated with high recurrence and mortality rates. Currently, there is no standard third-line treatment for metastatic gastric cancer. In this report, we present the case of a 69-year-old man with advanced gastric cancer, whose tumor was negative for human epidermal growth factor receptor 2 (HER2) according to immunohistochemical analysis. Next-generation sequencing performed on paraffin sections of the postoperative tumor samples indicated the presence of the ERBB3 V104L mutation. The patient received irinotecan plus pyrotinib as a third-line therapy and achieved a progression-free survival of 7.6 months with a high quality of life. Therefore, the combined administration of irinotecan and pyrotinib may improve the clinical condition of patients with gastric cancer harboring an ERBB3 mutation. Moreover, ERBB3 could be a potential therapeutic target for gastric cancer.Keywords: ERBB3, gastric cancer, irinotecan, pyrotinib, third-line therapy |
topic |
erbb3 gastric cancer irinotecan pyrotinib third-line therapy. |
url |
https://www.dovepress.com/gastric-cancer-harboring-an-erbb3-mutation-treated-with-a-pyrotinibnda-peer-reviewed-article-OTT |
work_keys_str_mv |
AT dingk gastriccancerharboringanerbb3mutationtreatedwithapyrotinibndashirinotecancomboacasestudy AT chenx gastriccancerharboringanerbb3mutationtreatedwithapyrotinibndashirinotecancomboacasestudy AT liy gastriccancerharboringanerbb3mutationtreatedwithapyrotinibndashirinotecancomboacasestudy AT liw gastriccancerharboringanerbb3mutationtreatedwithapyrotinibndashirinotecancomboacasestudy AT yey gastriccancerharboringanerbb3mutationtreatedwithapyrotinibndashirinotecancomboacasestudy AT het gastriccancerharboringanerbb3mutationtreatedwithapyrotinibndashirinotecancomboacasestudy AT wangw gastriccancerharboringanerbb3mutationtreatedwithapyrotinibndashirinotecancomboacasestudy AT zhangh gastriccancerharboringanerbb3mutationtreatedwithapyrotinibndashirinotecancomboacasestudy |
_version_ |
1724331792275603456 |